Lv11
68 积分 2025-07-23 加入
Pharmacovigilance insights into drug-associated venous thromboembolism
3小时前
已完结
Updated insights on memory disorder associated risk of medication: A real-world pharmacovigilance analysis
6小时前
已完结
Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS)
4天前
已完结
Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation
30天前
已关闭
International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
1个月前
已关闭
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer
1个月前
已完结
International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial
1个月前
已关闭
Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC)
1个月前
已关闭
A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study
1个月前
已完结
Safety and efficacy of first-line XELIRI with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies
1个月前
已关闭
皖公网安备34019202002308
